Abstract
43049 Efficacy and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Measure Up 1, Measure Up 2, and AD Up Phase 3 Clinical Trials at 52 Weeks
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have